Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients (Q46781791)
Jump to navigation
Jump to search
scientific article published in November 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients |
scientific article published in November 2005 |
Statements
1 reference
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients (English)
1 reference
Rakesh K Jain
1 reference
David T Scadden
1 reference
Mari Mino-Kenudson
1 reference
Lawrence S Blaszkowsky
1 reference
Lance L Munn
1 reference
Emmanuelle di Tomaso
1 reference
Christopher G Willett
1 reference
Yves Boucher
1 reference
Dan G Duda
1 reference
Ricky T Tong
1 reference
Sergey V Kozin
1 reference
Lucine Petit
1 reference
Daniel C Chung
1 reference
Dushyant V Sahani
1 reference
Sanjeeva P Kalva
1 reference
Kenneth S Cohen
1 reference
Alan J Fischman
1 reference
Jeffrey W Clark
1 reference
David P Ryan
1 reference
Andrew X Zhu
1 reference
Paul C Shellito
1 reference
Gregory Y Lauwers
1 reference
1 November 2005
1 reference
23
1 reference
31
1 reference
8136-8139
1 reference